Industry Report: Advanced Therapy Market May Triple by 2030

Key Takeaways

• Advanced therapies projected to triple from 61 to ~180 by 2030.
• 78% of practices treat 11+ advanced therapy patients.
• 96% of respondents favor community‑based delivery model.
• 48% of community professionals spend 1‑2 years preparing.
• Pipeline now includes cardiovascular, diabetes, and Alzheimer’s therapies.

Pulse Analysis

The 2026 Advanced Therapy Report from Cardinal Health paints a vivid picture of a market on the brink of exponential expansion. With 61 cell and gene therapies currently cleared by the FDA, analysts now expect that figure to approach 180 by 2030—a three‑fold increase driven by a surge of candidates targeting chronic diseases such as heart failure, type‑2 diabetes, and Alzheimer’s. This diversification moves the field beyond its early oncology and hematology focus, promising new revenue streams for biotech firms while raising the stakes for manufacturers to scale production and supply chains.

Equally transformative is the shift from academic medical centers to community‑based infusion sites. The report, based on responses from 160 physicians and administrators, shows that 78% of practices already treat more than ten advanced‑therapy patients, and 96% of health‑system leaders believe a decentralized model will boost capacity. Nearly half of community clinicians spend one to two years preparing for these complex administrations, underscoring the growing expertise outside traditional hubs. Decentralization promises faster patient access, reduced travel burdens, and a broader safety net for underserved regions.

These dynamics compel pharmaceutical companies to rethink go‑to‑market strategies. Partnerships with specialty pharmacies, contract infusion networks, and regional health systems will become essential to reach the projected 180‑plus therapies. At the same time, payers must adapt reimbursement models to accommodate outpatient administration costs and the longer training cycles reported by clinicians. Investors are likely to reward firms that build scalable logistics platforms and demonstrate real‑world outcomes in community settings, positioning advanced therapies as a mainstream pillar of chronic‑disease management by the end of the decade.